JAMA Dermatology : Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab vs Ipilimumab Alone for Unresectable Melanoma
Manage episode 221674254 series 1421505
Interview with Ivo Abraham, PhD, author of Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma
360 episodes available. A new episode about every 3 days averaging 14 mins duration .